PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786868
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786868
U.S. Central Nervous System Therapeutics Market Size, Share, Trends, & Industry Analysis Report, By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, and By Distribution Channel- Market Forecast, 2025-2034
The U.S. central nervous system therapeutics market size is expected to reach USD 84.86 Billion by 2034, according to a new study by Polaris Market Research. The report "US Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, By Distribution Channel - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Central Nervous System (CNS) therapeutics refers to treatments aimed at managing and alleviating disorders affecting the brain, spinal cord, and nerves, such as depression, epilepsy, Parkinson's disease, and Alzheimer's. These therapies include medications, biologics, and emerging digital and precision medicine approaches designed to improve neurological function and quality of life.
The integration of digital health and telemedicine is driving the growth. The US is leading the way in integrating digital health tools into the management of CNS disorders. The rapid rise of telemedicine more patients now have access to mental health consultations, therapy sessions, and medication management from their homes with rise in telemedicine. Mobile apps, wearable devices, and digital platforms are increasingly used to track symptoms, monitor adherence, and support behavioral therapy. For conditions such as depression, anxiety, and epilepsy, these tools provide real-time insights and enable personalized treatment plans. Additionally, insurers are beginning to reimburse digital treatments, encouraging wider adoption. Digital integration is becoming a key differentiator in the CNS therapeutics space with patients expecting convenience and real-time care. The combination of advanced technology, high smartphone usage, and a supportive regulatory environment drives the market.
The US Food and Drug Administration (FDA) plays a crucial role in accelerating the growth of the CNS therapeutics market through programs like Fast Track, Breakthrough Therapy, and Accelerated Approval. These initiatives are designed to speed up the review of drugs for serious CNS conditions with unmet medical needs, such as ALS, Alzheimer's, and treatment-resistant depression. Recent high-profile drug approvals in the US demonstrate the country's leadership in bringing innovative therapies to market quickly. Once approved, the large US healthcare system ensures swift commercial rollout, supported by robust pharmaceutical marketing and distribution channels. Patients further have relatively quick access to new drugs due to insurance coverage and patient assistance programs. This streamlined path from lab to patient encourages pharmaceutical companies to prioritize the US as their primary launch market. Consequently, the US continues to dominate global CNS drug commercialization and innovation, strengthening its market growth.
US Central Nervous System Therapeutics Market Report Highlights
The mental health segment accounted for 29.26% regional share during the forecast period driven by a surge in diagnosed cases of depression, anxiety, bipolar disorder, and PTSD.
The hospital pharmacy segment accounted USD 16.50 billion revenue in 2024 as hospital pharmacies are the leading distribution channel for CNS therapeutics in the country, particularly for acute and complex neurological conditions.
The global key market players are AstraZeneca plc; Biogen Inc.; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Neuraxpharm; Novartis AG; Otsuka Pharmaceutical Co., Ltd; Pfizer Inc.; Takeda Pharma Company Ltd; Teva Pharmaceutical Industries Ltd.
Polaris market research has segmented the US Central Nervous System Therapeutics Market report based on Disease, drug class, and distribution channel:
By Disease (Revenue - USD Billion, 2020-2034)
Neurovascular Diseases
CNS Trauma
Mental Health
Neurodegenerative Diseases
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Huntington's Disease
Amyotrophic Lateral Sclerosis
Others
Infectious Diseases
CNS Cancer
Others
By Drug Class (Revenue - USD Billion, 2020-2034)
Anesthetics
Anticonvulsants
Antiemetic
CNS Stimulants
Pain Relievers
Others
By Distribution Channel (Revenue - USD Billion, 2020-2034)
Hospital Pharmacy
Retail Pharmacy
Other
Table of Contents
1. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET-REPORT OVERVIEW
- 1.1. SCOPE OF THE REPORT
- 1.2. MARKET SEGMENT ANALYSIS
- 1.3. REGULATORY SCENARIO BY REGION/COUNTRY
- 1.4. MARKET INVESTMENT SCENARIO STRATEGIC
- 1.5. MARKET ANALYSIS BY DISEASE (USD MILLION)
- 1.5.1 US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DISEASE (2025-2034)
- 1.5.2 NEUROVASCULAR DISEASES
- 1.5.3 CNS TRAUMA
- 1.5.4 MENTAL HEALTH
- 1.5.5 NEURODEGENERATIVE DISEASES
- 1.5.5.1 ALZHEIMER'S DISEASE
- 1.5.5.2 PARKINSON'S DISEASE
- 1.5.5.3 MULTIPLE SCLEROSIS
- 1.5.5.4 HUNTINGTON'S DISEASE
- 1.5.5.5 AMYOTROPHIC LATERAL SCLEROSIS
- 1.5.5.6 OTHERS
- 1.5.6 INFECTIOUS DISEASES
- 1.5.7 CNS CANCER
- 1.5.8 OTHERS
- 1.6. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DISEASE IN 2025 & 2034
- 1.7. MARKET ANALYSIS BY DRUG CLASS (USD MILLION)
- 1.7.1 US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DRUG CLASS (2025-2034)
- 1.7.2 ANESTHETICS
- 1.7.3 ANTICONVULSANTS
- 1.7.4 ANTIEMETIC
- 1.7.5 CNS STIMULANTS
- 1.7.6 PAIN RELIEVERS
- 1.7.7 OTHERS
- 1.8. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DRUG CLASS IN 2025 & 2034
- 1.9. MARKET ANALYSIS BY DISTRIBUTION CHANNEL (USD MILLION)
- 1.9.1 US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DISTRIBUTION CHANNEL (2025-2034)
- 1.9.2 HOSPITAL PHARMACIES
- 1.9.3 RETAIL PHARMACIES
- 1.9.4 OTHERS
- 1.10. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DISTRIBUTION CHANNEL IN 2025 & 2034
2. DRIVER RESTRAINT CHALLENGE AND OPPORTUNITIES OF CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET
- 2.1. DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
- 2.1.1 MARKET DRIVER ANALYSIS
- 2.1.2 MARKET RESTRAINT ANALYSIS
- 2.1.3 MARKET OPPORTUNITY
- 2.1.4 MARKET CHALLENGES
3. US GROWTH TRENDS
- 3.1. INDUSTRY TRENDS
- 3.1.1 SWOT ANALYSIS
- 3.1.1.1 STRENGTHS
- 3.1.1.2 WEAKNESSES
- 3.1.1.3 OPPORTUNITIES
- 3.1.1.4 THREATS
- 3.1.2 PESTEL ANALYSIS
- 3.1.2.1 POLITICAL LANDSCAPE
- 3.1.2.2 ECONOMIC LANDSCAPE
- 3.1.2.3 SOCIAL LANDSCAPE
- 3.1.2.4 TECHNOLOGICAL LANDSCAPE
- 3.1.2.5 ENVIRONMENTAL LANDSCAPE
- 3.1.2.6 LEGAL LANDSCAPE
- 3.1.3 PORTER'S FIVE FORCES ANALYSIS
- 3.1.3.1 BARGAINING POWER OF SUPPLIERS
- 3.1.3.2 BARGAINING POWER OF BUYERS
- 3.1.3.3 THREAT OF SUBSTITUTE
- 3.1.3.4 THREAT OF NEW ENTRANT
- 3.1.3.5 COMPETITIVE RIVALRY
- 3.1.1 SWOT ANALYSIS
- 3.2. POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4. COVID-19 IMPACT
- 4.1. COVID-19 IMPACT
- 4.2. COVID V, U, W AND L ANALYSIS
- 4.2.1 COVID V ANALYSIS
- 4.2.2 COVID U ANALYSIS
- 4.2.3 COVID L ANALYSIS
- 4.2.4 COVID W ANALYSIS
5. COMPANIES ANALYSIS
- 5.1. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, SALES AREA, PRODUCT TYPE
- 5.2. MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET
- 5.3. COMPANIES LIST
6. EXCEUTIVE SUMMARY
7. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET FORECAST, 2021-2034, (USD MILLION)
- 7.1. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET
8. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY DISEASE (2021-2034), (USD MILLION)
- 8.1. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY DISEASE (2021-2027)
- 8.2. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY DISEASE (2028-2034)
9. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY NEURODEGENERATIVE DISEASES (2021-2034), (USD MILLION)
- 9.1. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY NEURODEGENERATIVE DISEASES (2021-2027)
- 9.2. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY NEURODEGENERATIVE DISEASES (2028-2034)
10. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY DRUG CLASS (2021-2034), (USD MILLION)
- 10.1. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY DRUG CLASS (2021-2027)
- 10.2. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY DRUG CLASS (2028-2034)
11. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (2021-2034), (USD MILLION)
- 11.1. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (2021-2027)
- 11.2. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (2028-2034)
111. COMPANY PROFILES
- 111.1. BIOGEN INC.
- 111.1.1 COMPANY DETAILS
- 111.1.2 FINANCIAL (USD MILLION)
- 111.1.3 PRODUCT SUMMARY
- 111.1.4 RECENT DEVELOPMENTS
- 111.2. OTSUKA PHARMACEUTICAL CO., LTD.
- 111.2.1 COMPANY DETAILS
- 111.2.2 FINANCIAL (USD MILLION)
- 111.2.3 PRODUCT SUMMARY
- 111.2.4 RECENT DEVELOPMENTS
- 111.3. ELI LILLY AND COMPANY.
- 111.3.1 COMPANY DETAILS
- 111.3.2 FINANCIAL (USD MILLION)
- 111.3.3 PRODUCT SUMMARY
- 111.3.4 RECENT DEVELOPMENTS
- 111.4. MERCK & CO INC.
- 111.4.1 COMPANY DETAILS
- 111.4.2 FINANCIAL (USD MILLION)
- 111.4.3 PRODUCT SUMMARY
- 111.4.4 RECENT DEVELOPMENTS
- 111.5. ASTRAZENECA PLC.
- 111.5.1 COMPANY DETAILS
- 111.5.2 FINANCIAL (USD MILLION)
- 111.5.3 PRODUCT SUMMARY
- 111.5.4 RECENT DEVELOPMENTS
- 111.6. TAKEDA PHARMACEUTICAL COMPANY.
- 111.6.1 COMPANY DETAILS
- 111.6.2 FINANCIAL (USD MILLION)
- 111.6.3 PRODUCT SUMMARY
- 111.6.4 RECENT DEVELOPMENTS
- 111.7. NOVARTIS AG.
- 111.7.1 COMPANY DETAILS
- 111.7.2 FINANCIAL (USD MILLION)
- 111.7.3 PRODUCT SUMMARY
- 111.7.4 RECENT DEVELOPMENTS
- 111.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 111.8.1 COMPANY DETAILS
- 111.8.2 FINANCIAL (USD MILLION)
- 111.8.3 PRODUCT SUMMARY
- 111.8.4 RECENT DEVELOPMENTS
- 111.9. JOHNSON & JOHNSON.
- 111.9.1 COMPANY DETAILS
- 111.9.2 FINANCIAL (USD MILLION)
- 111.9.3 PRODUCT SUMMARY
- 111.9.4 RECENT DEVELOPMENTS
- 111.10. PFIZER INC.
- 111.10.1 COMPANY DETAILS
- 111.10.2 FINANCIAL (USD MILLION)
- 111.10.3 PRODUCT SUMMARY
- 111.10.4 RECENT DEVELOPMENTS
- 111.11. NEURAXPHARM.
- 111.11.1 COMPANY DETAILS
- 111.11.2 FINANCIAL (USD MILLION)
- 111.11.3 PRODUCT SUMMARY
- 111.11.4 RECENT DEVELOPMENTS
112. CONCLUSION
113. REFERENCE LINK
114. ANALYST SUGGESTIONS AND RECOMMENDATIONS
115. APPENDIX
- 115.1. METHODOLOGY
- 115.2. RESEARCH DATA SOURCE
- 115.2.1 SECONDARY DATA
- 115.2.2 KEY DATA FROM SECONDARY
- 115.2.3 PRIMARY DATA
- 115.2.4 KEY DATA FROM PRIMARY
- 115.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
- 115.2.6 MARKET ESTIMATION
- 115.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
- 115.2.8 LEGAL DISCLAIMER
116. RESEARCH SCOPE
LIST OF TABLES
- TABLE 1. MARKET SEGMENT
- TABLE 2. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET GROWTH RATE BY DISEASE (USD MILLION) (2025-2034)
- TABLE 3. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET GROWTH RATE BY NEURODEGENERATIVE DISEASES (USD MILLION) (2025-2034)
- TABLE 4. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET GROWTH RATE BY DRUG CLASS (USD MILLION) (2025-2034)
- TABLE 5. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET GROWTH RATE BY DISTRIBUTION CHANNEL (USD MILLION) (2025-2034)
- TABLE 6. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET - MARKET SNAPSHOT & KEY BUYING CRITERIA, 2025 - 2034
- TABLE 7. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (USD MILLION) (2021-2027)
- TABLE 8. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (USD MILLION) (2028-2034)
- TABLE 9. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION) BY DISEASE, (2021-2027)
- TABLE 10. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DISEASE, (2021-2027)
- TABLE 11. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION) BY DISEASE, (2028-2034)
- TABLE 12. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DISEASE, (2028-2034)
- TABLE 13. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION) BY NEURODEGENERATIVE DISEASES, (2021-2027)
- TABLE 14. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY NEURODEGENERATIVE DISEASES, (2021-2027)
- TABLE 15. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION) BY NEURODEGENERATIVE DISEASES, (2028-2034)
- TABLE 16. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY NEURODEGENERATIVE DISEASES, (2028-2034)
- TABLE 17. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION) BY DRUG CLASS, (2021-2027)
- TABLE 18. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DRUG CLASS, (2021-2027)
- TABLE 19. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION) BY DRUG CLASS, (2028-2034)
- TABLE 20. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DRUG CLASS, (2028-2034)
- TABLE 21. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION) BY DISTRIBUTION CHANNEL, (2021-2027)
- TABLE 22. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DISTRIBUTION CHANNEL, (2021-2027)
- TABLE 23. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION) BY DISTRIBUTION CHANNEL, (2028-2034)
- TABLE 24. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE BY DISTRIBUTION CHANNEL, (2028-2034)
- TABLE 25. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION) BY REGION, (2021-2027)
LIST OF FIGURES
- FIGURE 1. MARKET OVERVIEW
- FIGURE 2. DROC OF CENTRAL NERVOUS SYSTEM THERAPEUTICS ANALYSIS
- FIGURE 3. SWOT ANALYSIS
- FIGURE 4. PESTEL ANALYSIS
- FIGURE 5. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 6. COVID V, U, W AND L ANALYSIS
- FIGURE 7. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2021-2027), (USD MILLION)
- FIGURE 8. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2028-2034), (USD MILLION)
- FIGURE 9. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2021-2027), (USD MILLION), BY DISEASE
- FIGURE 10. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2027), BY DISEASE
- FIGURE 11. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2028-2034), (USD MILLION), BY DISEASE
- FIGURE 12. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2034), BY DISEASE
- FIGURE 13. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2021-2027), (USD MILLION), BY NEURODEGENERATIVE DISEASES
- FIGURE 14. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2027), BY NEURODEGENERATIVE DISEASES
- FIGURE 15. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2028-2034), (USD MILLION), BY NEURODEGENERATIVE DISEASES
- FIGURE 16. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2034), BY NEURODEGENERATIVE DISEASES
- FIGURE 17. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2021-2027), (USD MILLION), BY DRUG CLASS
- FIGURE 18. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2027), BY DRUG CLASS
- FIGURE 19. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2028-2034), (USD MILLION), BY DRUG CLASS
- FIGURE 20. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2034), BY DRUG CLASS
- FIGURE 21. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2021-2027), (USD MILLION), BY DISTRIBUTION CHANNEL
- FIGURE 22. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2027), BY DISTRIBUTION CHANNEL
- FIGURE 23. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2028-2034), (USD MILLION), BY DISTRIBUTION CHANNEL
- FIGURE 24. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2034), BY DISTRIBUTION CHANNEL
- FIGURE 25. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2021-2027), (USD MILLION), BY REGION
- FIGURE 26. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2027), BY REGION
- FIGURE 27. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE (USD MILLION), (2028-2034), (USD MILLION), BY REGION
- FIGURE 28. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, (2034), BY REGION
